Mirum Pharmaceuticals
MIRM | NASDAQ
$91.58
-$2.41 (-2.56%)
At close: Nov 16, 2026, 4:00 PM ET
$91.58
$0.00 (0.00%)
After-hours:
Nov 16, 2026, 7:30 PM ET
Mirum Pharmaceuticals Company Profile
Company profile explainedCompany Profile
Mirum Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to discovering and commercializing groundbreaking therapies for serious rare and orphan conditions. Its lead experimental drug, LIVMARLI, an oral treatment, is currently undergoing trials for progressive familial intrahepatic cholestasis (PFIC), Alagille syndrome, and biliary atresia. Furthermore, the company is advancing Volixibat to address intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Founded in 2018, Mirum Pharmaceuticals, Inc. operates from its headquarters in Foster City, California.
Key Executives
| Name | Position |
|---|---|
| Christopher Peetz | Chief Executive Officer & Director |
| Douglas T. Sheehy | Chief Legal Officer & Secretary |
| Eric H. Bjerkholt | Chief Financial Officer |
| Erin Campany | Chief People Officer |
| Peter Radovich | Chief Operating Officer & President |
| Andrew McKibben | Senior Vice President, Strategic Finance & Investor Relations |
| Jean-Luc Girardet | Chief Technical Officer |
| Joanne J. Quan | Chief Medical Officer |
| Lara Longpre | Chief Development Officer |
| Meredith Kiernan | Senior Director of Global Corporate Communications |
| Vinita Kumar | Senior Vice President of Quality |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 26, 2026 | 8-K | Current Report |
| Oct 19, 2026 | 4 | Filing |
| Oct 14, 2026 | 4 | Filing |
| Oct 13, 2026 | 8-K | Current Report |
| Oct 06, 2026 | 4 | Filing |
| Sep 28, 2026 | 8-K | Current Report |
| Sep 22, 2026 | 3 | Filing |
| Sep 15, 2026 | 4 | Filing |
| Sep 08, 2026 | 8-K | Current Report |
| Sep 03, 2026 | 4 | Filing |
Mirum Pharmaceuticals
| Country | United States |
| IPO Date | Jul 18, 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 433 |
| CEO | Christopher Peetz |
Contact Details
989 East Hillsdale Boulevard Foster City,
California 94404 United States
Stock Details
| Ticker Symbol | MIRM |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001759425 |
| CUSIP Number | 604749101 |
| ISIN Number | US6047491013 |
| SIC Code | 2834 |
Recent News
- 5 days ago / zacks.comMIRM's Brelovitug Scores Second Phase III Win, Nears BLA Filing in HDV
- 6 days ago / reuters.comMirum's liver infection drug lowers virus levels in second late-stage study
- 6 days ago / businesswire.comMirum Pharmaceuticals Announces Primary Endpoint Met in AZURE-4 Phase 3 Study and Highlights Long-Term Brelovitug Data Presented at AASLD
- 13 days ago / seekingalpha.comMirum Pharmaceuticals, Inc. (MIRM) Q3 2026 Earnings Call Transcript
- 13 days ago / marketbeat.comMirum Pharmaceuticals Q3 Earnings Call Highlights
- 13 days ago / zacks.comHere's What Key Metrics Tell Us About Mirum Pharmaceuticals (MIRM) Q3 Earnings
- 13 days ago / zacks.comMirum Pharmaceuticals, Inc. (MIRM) Reports Q3 Loss, Tops Revenue Estimates
- 15 days ago / businesswire.comMirum Pharmaceuticals Showcases Momentum Across Rare Liver Disease Portfolio with New Data at AASLD's The Liver Meeting® 2026
- 21 days ago / zacks.comMirum Pharmaceuticals, Inc. (MIRM) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
- 1 month ago / zacks.comMirum's Livmarli Meets Phase III Goal in Ultra-Rare Liver Diseases
Add to Watchlist
Select watchlists to add or remove MIRM